DEFA14A: Repare Therapeutics Acquired by Xeno Acquisition Corp.

Repare Therapeutics Inc. has entered into an Arrangement Agreement to be acquired by Xeno Acquisition Corp. for an estimated $1.82 per share cash plus contingent value rights.

Summary

• Repare Therapeutics Inc. (the Company) will be acquired by Xeno Acquisition Corp. (Purchaser), a wholly-owned subsidiary of XenoTherapeutics, Inc. (Xeno), through a court-approved plan of arrangement.
• Shareholders are expected to receive an estimated cash payment of approximately $1.82 per Common Share at closing, which is subject to deductions for transaction costs, outstanding liabilities, and a transaction fee to Xeno.
• In addition to the cash payment, each shareholder will receive one non-transferable Contingent Value Right (CVR) for each Common Share, entitling them to a pro rata portion of potential future cash payments.
• CVR payments will include 100% of certain additional receivables within 90 days post-closing, a declining percentage (90% to 75%) of net proceeds from existing partnerships over 10 years, and 100% or 50% of net proceeds from the disposition of specific product candidates/intellectual property depending on the program and timing.
• The Company's Transaction Committee, comprised of independent directors, and the Board of Directors have unanimously approved the transaction and recommend shareholders vote in favor.
• The transaction requires approval from at least 66 2/3% of votes cast by shareholders and a majority of votes cast excluding certain interested parties.
• Company officers and directors, holding approximately 0.25% of outstanding Common Shares, have entered into voting and support agreements in favor of the transaction.
• The Company initiated a strategic re-prioritization in August 2024, involving the discontinuance and orderly wind-up of its business, including concluding R&D activities, monetizing IP/assets, and laying off nearly all its workforce.

Sentiment

Score: 3

Explanation: The sentiment is generally negative due to the company's strategic wind-down, cessation of R&D, and significant layoffs, indicating a failure of its previous business model. While the acquisition provides an exit and potential future upside via CVRs, the core business is being dismantled. The CVRs are speculative and non-transferable, limiting their immediate value and certainty for shareholders.

Positives

• Provides a clear exit strategy for shareholders with an immediate cash payment component.
• Contingent Value Rights (CVRs) offer potential future upside from existing partnerships and the monetization of specific product candidates and intellectual property.
• The transaction received unanimous approval and recommendation from the Company's independent Transaction Committee and the full Board of Directors, suggesting favorable terms for shareholders.
• XOMA Royalty Corporation (XRC) has unconditionally and irrevocably guaranteed the full and timely performance of Xeno and Purchaser's obligations under the Arrangement Agreement.

Negatives

• The estimated cash payment of $1.82 per share is subject to various deductions, making the final amount uncertain until immediately prior to closing.
• The CVRs are non-transferable, which significantly limits their liquidity and makes their market valuation challenging and speculative.
• Future CVR payments are contingent on the success of existing partnerships and the monetization of specific assets, with no assurance that any payments will be received.
• The Company has already ceased research and development activities and laid off most of its workforce, indicating a wind-down of its core business rather than a strategic growth acquisition.
• A termination fee of $2,000,000 is payable by the Company to the Purchaser under certain specified circumstances, such as accepting a Superior Proposal.

Risks

• Failure to obtain the required shareholder approval (66 2/3% of votes cast and a majority excluding interested parties).
• Failure to obtain necessary interim and final orders from the Superior Court of Quebec.
• Shareholders exercising dissent rights exceeding 5% of the outstanding Common Shares could prevent the transaction.
• Inaccuracies in representations and warranties or non-compliance with covenants by either party could lead to termination or other liabilities.
• The occurrence of a Material Adverse Change prior to the Effective Time could allow the Purchaser to terminate the agreement.
• The Closing Net Cash must be greater than or equal to zero; if not, the Purchaser is not obligated to make payments under the plan of arrangement.
• CVR payments are highly speculative and contingent on future events, and there is no guarantee that any CVR proceeds will be realized.
• The non-transferability of CVRs means holders cannot sell them on an open market, limiting their value and liquidity.
• Potential for Transaction Litigation challenging the Arrangement, which could delay or prevent closing and incur costs.
• Changes to applicable Laws or governmental positions could materially affect the Company's 'Discontinuance' strategy or the transaction.

Future Outlook

The Company is undergoing a strategic re-prioritization, discontinuing research and development activities, and aiming to monetize its existing intellectual property and assets with the ultimate objective of distributing all proceeds to shareholders. The acquisition by Xeno Acquisition Corp. is part of this wind-up and monetization strategy, with future potential payments tied to CVRs from existing partnerships and future asset dispositions over a 10-year period.

Management Comments

• "The Company's transaction committee comprised entirely of independent directors of the board of directors of the Company following receipt and review of the opinion of the Transaction Committee's financial advisors, determined that the Arrangement is fair to the Shareholders, and that the Arrangement is in the best interests of the Company."
• "The Board, after consultation with the Company's management and legal advisors and, following the receipt and review of the unanimous recommendation from the Transaction Committee and the opinion of the Transaction Committee's financial advisors, has unanimously approved the Transaction and determined that the Transaction is in the best interest of the Company and is fair to the Shareholders."
• "The Board has unanimously resolved to recommend that the Shareholders vote in favor of the Transaction, subject to the terms and conditions contained in the Agreement."

Industry Context

This acquisition represents a strategic exit for Repare Therapeutics, a biotech company, rather than a growth-oriented merger. The explicit focus on monetizing existing intellectual property and winding down research and development activities suggests a shift away from active drug development for Repare. The Contingent Value Right (CVR) structure is a common mechanism in biotech acquisitions where the acquiring company seeks to share future risks and rewards associated with pipeline assets. The involvement of XOMA Royalty Corporation (XRC) as a guarantor further aligns with a strategy focused on royalty streams and asset monetization, consistent with Repare's stated 'Discontinuance' strategy.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) is a common mechanism in biotech acquisitions, particularly when the value of pipeline assets is uncertain or requires further development/monetization efforts. Similar structures have been observed in acquisitions such as Sanofi's acquisition of Principia Biopharma or Roche's acquisition of Spark Therapeutics, where CVRs were utilized to bridge valuation gaps related to clinical milestones.
• The estimated cash payment of $1.82 per share, combined with CVRs, should be assessed against the company's historical stock performance and peer valuations for similar-stage biotech companies undergoing strategic exits or asset monetization. Without specific peer data, a direct comparison is challenging, but the overall structure is standard for such scenarios.
• The requirement for a 66 2/3% shareholder approval is a standard threshold for plans of arrangement in Quebec, Canada, and is consistent with corporate governance best practices for significant corporate transactions.
• The 5% dissent rights threshold is a common protective measure for acquirers, ensuring a high level of shareholder consensus for the transaction to proceed without excessive dissenting shares.

Management Changes

Corporate Governance

Legal Proceedings

• The Company must promptly notify the Purchaser of any 'Transaction Litigation' (any proceeding by a third party against the Company, Board, or officers related to the Arrangement). The Company must allow the Purchaser to participate in the defense and cannot settle without the Purchaser's prior written consent.

Related Party Transactions

• XOMA Royalty Corporation (XRC), a party to the Arrangement Agreement, has unconditionally and irrevocably guaranteed the full and timely performance of Xeno and Purchaser's obligations under the Agreement.
• Voting and Support Agreements have been entered into between the Purchaser and the Company's officers and directors, obligating them to vote their shares in favor of the Arrangement.

Stakeholder Impact

• Shareholders: Will receive an estimated cash payment and non-transferable CVRs, providing immediate liquidity and potential, albeit speculative, future upside from asset monetization. The non-transferability of CVRs limits their immediate market value.
• Employees: The Company has already laid off 'nearly all of its workforce' as part of its 'Discontinuance' strategy, indicating a significant negative impact on employment.
• Management/Directors: Current directors and officers will resign upon closing, but their D&O insurance and indemnification rights are preserved for six years post-acquisition.
• Customers/Partners: Existing partnerships (e.g., with Bristol-Myers Squibb, Debiopharm, DCx Biotherapeutics) are expected to continue to generate proceeds, which will contribute to CVR payments, suggesting continuity for these relationships.
• Creditors: Outstanding liabilities are factored into the Closing Net Cash calculation, implying their settlement as part of the transaction.

Next Steps

• The Company will apply for an Interim Order from the Superior Court of Quebec.
• The Company will prepare and mail a Circular (information circular and proxy statement) to shareholders.
• A special meeting of shareholders will be convened to vote on the Arrangement Resolution.
• If approved by shareholders, the Company will apply for a Final Order from the Superior Court of Quebec.
• The closing of the transaction (Effective Date) is expected to occur on the third business day following receipt of the Final Order.
• The Purchaser will cause the Company to be delisted from Nasdaq and deregistered under the US Exchange Act.
• Potential future payments to CVR holders will be made based on proceeds from existing partnerships and asset dispositions until the CVR Expiration Date (tenth anniversary of Closing).

Key Dates

Recommendation

The company is undergoing a strategic wind-down, ceasing R&D, and laying off most of its workforce, indicating a fundamental shift away from its previous growth model. The acquisition provides an exit, but the immediate cash component is relatively low, and the CVRs are highly speculative, non-transferable, and subject to significant uncertainty regarding future payments. Given the cessation of core operations and the speculative nature of future value, a seasoned investor would likely recommend selling to realize the immediate cash value and avoid the long-term uncertainty and illiquidity of the CVRs.

Keywords

Acquisition, Merger, Biotech, Pharmaceuticals, Contingent Value Rights, CVR, Shareholder Agreement, Corporate Governance, Strategic Reprioritization, Asset Monetization, SEC Filing, Repare Therapeutics, XenoTherapeutics